A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...
In October 2025, Terns Pharmaceuticals announced strongly positive Phase 1 data for TERN-701 in chronic myeloid leukemia, with a 75% major molecular response rate by 24 weeks and no dose-limiting ...
Terns Pharmaceuticals (TERN) is getting attention after announcing that early-stage trial results for its CML drug candidate, TERN-701, were selected for oral presentation at this year's American ...
Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...
The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...
Investing.com -- Terns Pharmaceuticals (NASDAQ:TERN) stock surged 28% Tuesday, extending its two-day gain to 120% following positive clinical data for its TERN-701 treatment in relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback